SUBSCRIBE
SUBSCRIBE

Johnson & Johnson Family of Companies

NEWS
It's Finally Happening: Johnson & Johnson Pays $30 Billion for Actelion, Will Spin Off R&D Unit With $1 Billion Cash
Deals
It’s Finally Happening: Johnson & Johnson Pays $30 Billion for Actelion, Will Spin Off R&D Unit With $1 Billion Cash
January 26, 2017
 · 
3 min read
Massachusetts' Biostage Slashes 71% of Staff, Evaluating Strategic Alternatives
Pharm Country
Why Pfizer Could be Johnson & Johnson’s Biggest Headache in 2017
January 25, 2017
 · 
2 min read
Wall Street's Top Biotech Analyst Loves These 2 Life Science Stocks
Business
Earnings Preview: Here’s a Look at What to Expect From 7 Biopharmas
January 23, 2017
 · 
3 min read
Pharm Country
5 Most Important Drugs To Johnson & Johnson In 2017
January 19, 2017
 · 
1 min read
Pharm Country
A Look at Whether Johnson & Johnson Passes Warren Buffet’s Acquisition Test
January 17, 2017
 · 
1 min read
Biotech Beach
Johnson & Johnson’s Device Subsidiary Gets Into Value-Based Analytics
January 11, 2017
 · 
1 min read
Pharm Country
How Trump Can Propel Johnson & Johnson to New Heights
January 11, 2017
 · 
1 min read
Deals
Sanofi Sees No Opening to Actelion Talks After Johnson & Johnson Steps Back in
January 10, 2017
 · 
1 min read
Policy
Judge Halves $1 Billion Award In Johnson & Johnson Hip Implants Case
January 4, 2017
 · 
1 min read
Load More
AWARDS
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
JOBS
IN THE PRESS
Press Releases
European Commission approves TREMFYA® (guselkumab) for the treatment of children with plaque psoriasis, marking the first paediatric indication for an IL-23 inhibitor
December 22, 2025
 · 
14 min read
Press Releases
Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma
December 19, 2025
 · 
6 min read
Press Releases
U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)
December 18, 2025
 · 
33 min read
Press Releases
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results - December 15, 2025
December 16, 2025
 · 
1 min read
Press Releases
Link Cell Therapies Launches with Vision of Advancing CAR-T Therapies in Solid and Liquid Tumors
December 16, 2025
 · 
4 min read
Press Releases
U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*
December 15, 2025
 · 
20 min read
Press Releases
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI®▼ (teclistamab) plus DARZALEX® (daratumumab) subcutaneous formulation as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
December 10, 2025
 · 
18 min read
Press Releases
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
December 10, 2025
 · 
28 min read
Press Releases
Johnson & Johnson to Participate in the 44th Annual J.P. Morgan Healthcare Conference
December 9, 2025
 · 
1 min read
Press Releases
Earlier use of CARVYKTI®▼ (ciltacabtagene autoleucel) demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
December 8, 2025
 · 
15 min read
Load More